Another ‘Practice-Changing’ Study in High-Risk Bladder Cancer

By News Health
4 hours Ago

(MedPage Today) — BERLIN — Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) in patients with BCG-naive, high-risk non-muscle-invasive bladder…

Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118010

Author :

Publish date : 2025-10-17 20:54:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

'An adult weekender at Butlin's saved my life'

Exciting results from blood test for 50 cancers

Gene Therapy Shows Lasting Benefit for Children With Rare Disorder

Government Shutdown, Funding Cuts Threaten U.S. Disaster Preparedness, Experts Say

Does the AMA Have a Seat at Trump's Table?

Immunotherapy Gets 'Meaningful' Survival Win in Operable Gastric Cancer